ProQR Therapeutics (NASDAQ:PRQR) Upgraded to Hold at StockNews.com

StockNews.com upgraded shares of ProQR Therapeutics (NASDAQ:PRQRFree Report) from a sell rating to a hold rating in a research note released on Saturday morning.

Several other analysts also recently issued reports on the company. HC Wainwright reissued a buy rating and issued a $5.00 price target on shares of ProQR Therapeutics in a report on Friday, May 10th. Citigroup raised their target price on ProQR Therapeutics from $1.80 to $2.00 and gave the company a buy rating in a research note on Thursday, April 18th. Finally, Chardan Capital restated a buy rating and set a $2.50 price target on shares of ProQR Therapeutics in a research report on Friday, May 10th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of Moderate Buy and an average target price of $3.38.

Read Our Latest Stock Analysis on ProQR Therapeutics

ProQR Therapeutics Trading Up 1.0 %

PRQR stock opened at $1.94 on Friday. ProQR Therapeutics has a 1-year low of $1.11 and a 1-year high of $3.29. The firm has a fifty day moving average price of $2.13 and a two-hundred day moving average price of $1.97.

ProQR Therapeutics (NASDAQ:PRQRGet Free Report) last posted its quarterly earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). The business had revenue of $3.54 million during the quarter, compared to analyst estimates of $27.88 million. ProQR Therapeutics had a negative net margin of 260.75% and a negative return on equity of 61.58%. Equities research analysts expect that ProQR Therapeutics will post -0.37 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. EP Wealth Advisors LLC bought a new stake in shares of ProQR Therapeutics during the first quarter valued at about $26,000. Acadian Asset Management LLC acquired a new position in ProQR Therapeutics during the 1st quarter valued at about $56,000. RFG Advisory LLC acquired a new position in ProQR Therapeutics during the 1st quarter valued at about $73,000. BNP Paribas Financial Markets raised its position in shares of ProQR Therapeutics by 120.1% during the 1st quarter. BNP Paribas Financial Markets now owns 35,001 shares of the biopharmaceutical company’s stock worth $80,000 after buying an additional 19,100 shares in the last quarter. Finally, Monaco Asset Management SAM lifted its stake in shares of ProQR Therapeutics by 58.9% in the 3rd quarter. Monaco Asset Management SAM now owns 377,517 shares of the biopharmaceutical company’s stock worth $491,000 after acquiring an additional 140,000 shares during the period. Institutional investors and hedge funds own 32.65% of the company’s stock.

About ProQR Therapeutics

(Get Free Report)

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).

Featured Stories

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.